Rivastigmine analysis

Farlow, M., Potkin, S., Koumaras, B., Veach, J., Mirski, D. (2003) Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-wk, Alzheimer s disease trial. Arch. Neurol, 60, 843-848. 

Based on an electrocardiographic analysis of pooled data from four 26-week, phase III, multicenter, double-blind, placebo-controlled trials of rivastigmine (n = 2791), there were no adverse effects on cardiac function (19). Rivastigmine can therefore be safely given to patients with Alzheimer s disease, without the need for cardiac monitoring. 

Rivastigmine did not interact significantly with a wide range of concomitant medications prescribed for elderly patients with Alzheimer s disease, based on an analysis of 2459 patients (rivastigmine 1696, placebo 763) from four randomized placebo-controlled studies (23). However, the Breslow-Day analysis used in this study detected only differences in the odds ratios of rivastigmine versus placebo among patients taking concomitant medications. Thus, these results have to be cautiously interpreted. 

In contrast, analysis of population data from 70 subjects found that oestrogens did not affect rivastigmine pharmacokinetics. ... 

---